That study was a prospective, randomised, controlled, two-arm parallel group study with the purpose to evaluate lung function and asthma control in patients who were stepped down from the highest recommended dose of inhaled corticosteroid/long acting β2 agonist combination therapy.

Pierrel Research has been involved in the whole trial management, data management and statistical analysis and has made a decisive contribution to the successful conclusion of the study. That study is only one example of the dozen of international, multicentres clinical trials in COPD and Asthma indications, Pierrel Research has conducted over the last 3-4 years.

Our track record, among other indications, clearly documents a large, consolidated and competitive experience and expertise in the Respiratory Area. We can provide internal specialistic medical, regulatory and statistical advice on any clinical drug development programme in Pneumology. Finally we are proud to provide excellent and innovative technological solutions to either collect patient’s home PEF values and daily diary data or standardize and centralize spirometric data measurements at clinical site.